TY  - JOUR
AU  - Schlenk, Richard
AU  - Stegelmann, F.
AU  - Reiter, A.
AU  - Jost, E.
AU  - Gattermann, N.
AU  - Hebart, H.
AU  - Waller, C.
AU  - Hochhaus, A.
AU  - Platzbecker, U.
AU  - Schafhausen, P.
AU  - Blau, I. W.
AU  - Verbeek, W.
AU  - Heidel, F. H.
AU  - Werner, M.
AU  - Kreipe, H.
AU  - Teleanu, V.
AU  - Benner, A.
AU  - Döhner, H.
AU  - Grießhammer, M.
AU  - Döhner, K.
TI  - Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
JO  - Leukemia
VL  - 31
IS  - 4
SN  - 1476-5551
CY  - Basingstoke
PB  - Nature Publ. Group
M1  - DKFZ-2017-00130
SP  - 889-895
PY  - 2017
AB  - Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or thrombocytopenia and/or neutropenia. Subjects received pomalidomide 2.0 mg/day in cohort 1 (n=38) or 0.5 mg/day in cohort 2 (n=58). Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months. Response rates were 39
LB  - PUB:(DE-HGF)16
C6  - pmid:27774990
DO  - DOI:10.1038/leu.2016.299
UR  - https://inrepo02.dkfz.de/record/119376
ER  -